<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060098</url>
  </required_header>
  <id_info>
    <org_study_id>2104091</org_study_id>
    <nct_id>NCT01060098</nct_id>
  </id_info>
  <brief_title>T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade</brief_title>
  <official_title>T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rheumatoid Arthritis and Other Conditions Treated With Anti-TNFalpha Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to translate these findings into patients with rheumatoid arthritis and other
      conditions treated with anti-TNF (anti-tumor necrosis factor) therapy, such as psoriatic
      arthritis and ankylosing spondylitis. Patients from rheumatology clinics within NHS (National
      Health Service) trusts will be recruited. We will correlate disease activity assessed by
      clinical parameters, ultrasonography, and questionnaires with biomarkers in the blood and
      target tissues, such as synovium and skin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory arthritis particularly rheumatoid arthritis (RA), psoriatic arthritis and
      ankylosing spondylitis are potentially disabling conditions which cause joint pain, swelling
      and deformity and treatments are aimed at preventing these complications. Although treatment
      has improved with the advent of anti TNF alpha therapies, up to 30% of patients fail to
      respond to this treatment and in others, treatment is associated with significant side
      effects. The precise mechanisms of this remain unclear. In addition, there are no sensitive
      methods available to monitor or predict disease response to treatment aside from testing
      inflammatory markers in the blood. Understanding the mechanism of action and what governs
      response to anti TNF therapy will allow development of more specific therapies for
      inflammatory arthritis. Work in animal models of rheumatoid arthritis has characterised a
      novel cell type, Th17 cells, important in the inflammatory cascade which are affected in a
      particular way by anti TNF therapies and may underpin their mechanism of action and side
      effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Effector T Helper Type 17 Cells in Peripheral Blood</measure>
    <time_frame>Week 0, Week 12</time_frame>
    <description>The frequency of circulating Th17 cells was determined by IL17 enzyme-linked immunospot assay (Elispot) and flow cytometry (fluorescence-activated cell sorting (FACS)).</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <description>Participants with Rheumatoid arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ankylosing spondylitis</arm_group_label>
    <description>Participants with Ankylosing spondylitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriatic arthritis</arm_group_label>
    <description>Participants with Psoriatic arthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-TNF therapy (etanercept or adalimumab)</intervention_name>
    <description>Biological DMARD</description>
    <arm_group_label>Ankylosing spondylitis</arm_group_label>
    <arm_group_label>Psoriatic arthritis</arm_group_label>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <other_name>Enbrel</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Only anti-TNF na√Øve patients will be included in this study

          -  Patients between 18 to 80 years of age

          -  Patients due to start treatment with anti-TNF blocking agents - etanercept or
             adalimumab

        Patients with rheumatoid arthritis

          -  Only patients meeting the 1987 American College of Rheumatology (ACR) revised
             classification criteria for rheumatoid arthritis will be included

          -  Patients should have active rheumatoid arthritis, defined by an initial DAS28 score
             &gt;5.1

          -  Patients should have at least 1 joint suitable for synovial biopsy

          -  Patients can be on concurrent DMARDs but they should have been on a stable dose of
             DMARD for at least 1 month prior to study entry

          -  Patients can be on a concurrent dose of glucocorticoids (up to 10mg daily) and they
             should have been on a stable dose for at least 4 weeks prior to study entry

        Patients with psoriatic arthritis

          -  Patients should have a secure diagnosis of psoriatic arthritis determined by a
             rheumatologist

          -  Patients with psoriatic arthritis included in this study should have evidence of
             concurrent psoriatic skin lesions at the time of study entry

          -  Patients should have at least one joint suitable for synovial biopsy

          -  Patients can be on concurrent DMARDs - they should be on a stable dose of DMARD for at
             least 1 month prior to study entry

        Patients with Ankylosing spondylitis

          -  Patient should fulfil the Modified New York Criteria for diagnosis of ankylosing
             spondylitis

          -  Patients can be on concurrent NSAIDs

          -  Patients can be on concurrent DMARDs - they should be on a stable dose of DMARD for at
             least 1 month prior to study entry

        Exclusion Criteria:

          -  Patients who have been previously treated with anti-TNF therapy for whatever reason

          -  Patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who
             do not fulfil the diagnostic criteria for these conditions as above

          -  Patient who have received an intra-articular injection of steroids or have received an
             intra-muscular injection of depot steroid to treat disease flare in the preceding 4
             weeks prior to commencing anti-TNF therapy.

          -  Patients with intercurrent, active infection of any type, excluding the common cold
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonya Abraham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kennedy Institute Clinical Trials Unit, 4Wl, Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Hull DN, Cooksley H, Chokshi S, Williams RO, Abraham S, Taylor PC. Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. Arthritis Res Ther. 2016 Dec 23;18(1):303. doi: 10.1186/s13075-016-1197-5.</citation>
    <PMID>28010726</PMID>
  </results_reference>
  <results_reference>
    <citation>Hull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis. Clin Exp Immunol. 2015 Sep;181(3):401-6. doi: 10.1111/cei.12626. Epub 2015 Jun 23.</citation>
    <PMID>25766640</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 29, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <results_first_submitted>August 8, 2019</results_first_submitted>
  <results_first_submitted_qc>December 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rheumatoid Arthritis</title>
          <description>Participants with Rheumatoid arthritis anti-TNF therapy (etanercept or adalimumab): Biological DMARD</description>
        </group>
        <group group_id="P2">
          <title>Ankylosing Spondylitis</title>
          <description>Participants with Ankylosing spondylitis</description>
        </group>
        <group group_id="P3">
          <title>Psoriatic Arthritis</title>
          <description>Participants with Psoriatic arthritis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rheumatoid Arthritis</title>
          <description>Participants with Rheumatoid arthritis</description>
        </group>
        <group group_id="B2">
          <title>Ankylosing Spondylitis</title>
          <description>Participants with Ankylosing spondylitis</description>
        </group>
        <group group_id="B3">
          <title>Psoriatic Arthritis</title>
          <description>Participants with psoriatic arthritis</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="11.7"/>
                    <measurement group_id="B2" value="36.4" spread="11.8"/>
                    <measurement group_id="B3" value="50.9" spread="8.4"/>
                    <measurement group_id="B4" value="48.23" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Effector T Helper Type 17 Cells in Peripheral Blood</title>
        <description>The frequency of circulating Th17 cells was determined by IL17 enzyme-linked immunospot assay (Elispot) and flow cytometry (fluorescence-activated cell sorting (FACS)).</description>
        <time_frame>Week 0, Week 12</time_frame>
        <population>Patients with RA were studied at protocol visits during the initial 12 weeks of anti-TNF treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Participants with Rheumatoid arthritis</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis</title>
            <description>Participants with Ankylosing spondylitis</description>
          </group>
          <group group_id="O3">
            <title>Psoriatic Arthritis</title>
            <description>Participants with Psoriatic arthritis</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Effector T Helper Type 17 Cells in Peripheral Blood</title>
          <description>The frequency of circulating Th17 cells was determined by IL17 enzyme-linked immunospot assay (Elispot) and flow cytometry (fluorescence-activated cell sorting (FACS)).</description>
          <population>Patients with RA were studied at protocol visits during the initial 12 weeks of anti-TNF treatment</population>
          <units>spSFC/10^6</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466.4" spread="277.6"/>
                    <measurement group_id="O2" value="432" spread="474"/>
                    <measurement group_id="O3" value="450" spread="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="759.8" spread="510"/>
                    <measurement group_id="O2" value="651" spread="532"/>
                    <measurement group_id="O3" value="609" spread="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>week 0 compared to week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>week 0 compared to week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 0 compared to week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rheumatoid Arthritis</title>
          <description>Participants with Rheumatoid arthritis</description>
        </group>
        <group group_id="E2">
          <title>Ankylosing Spondylitis</title>
          <description>Participants with Ankylosing spondylitis</description>
        </group>
        <group group_id="E3">
          <title>Psoriatic Arthritis</title>
          <description>Participants with Psoriatic arthritis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sonya Abraham</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0)20 3313 4114</phone>
      <email>s.abraham@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

